Australia's most trusted
source of pharma news
Friday, 28 November 2025
Posted November 27 2025 PM
Semaglutide can’t cure Alzheimer’s after all. The GLP-1 agonist failed to reduce disease progression in two phase 3 trials, Novo Nordisk announced this week.
The research had always been a long shot. It was a “lottery ticket”, Novo Executive Vice President for Product and Portfolio Strategy, Ludovic Helfgott, told Reuters two months ago. However, markets were still disappointed: Novo’s stock fell about six per cent down on both the Danish and US exchanges.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.